Boston Scientific (NYSE:BSX) shares came under early pressure today after the medical device maker posted third-quarter sales that missed the consensus outlook and lowered its top-line guidance for the rest of the year – despite a 50% bump to its bottom line.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,